Anti-interleukin-2 receptor antibodies: Basiliximab and daclizumab

Nephrology Dialysis Transplantation

Volumn 16, Issue 9, 2001, Pages 1756-1760

  Pascual, Julio ^a   Marcén, Roberto ^a   Ortuño, Joaquín ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Basiliximab; Daclizumab; Monoclonal antibodies

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; OKT 3; PLACEBO; STEROID; THYMOCYTE ANTIBODY;

ARTICLE; BINDING COMPETITION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034850342     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.9.1756     Document Type: Article

References (31)

1. Disney APS. Cancer risk associated with ATG/OKT3 in renal transplantation
2. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts
3. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
4. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
5. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
6. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
7. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliimab, a chimeric anti-interleukin-2 receptor monoclonal antibody
8. Basiliximab (Simulect®) disminuye significativamente la incidencia de rechazo agudo en pacientes receptores de transplante renal que reciben terapia triple con azatioprina
9. Basiliximab (Simulect®) es seguro y eficaz en combinación con terapia triple de Sandimmun Neoral®, esteroides y Cellcept® en pacientes receptores de transplante renal
10. Retirada rápida de esteroides versus una pauta de esteroides estándar en pacientes tratados con Simulect®, Sandimmun Neoral® y micofenolato mofetil para la prevención del rechazo agudo en transplante renal
11. Controlled trial of IL-2R antibody basiliximab (Simulect) versus low dose OKT3 in cadaver kidney transplant recipients
12. A randomized prospective trial of OKT3 vs basiliximab for induction therapy in renal transplantation
13. Improved outcome in renal transplant recipients treated with Simulect versus OKT3 induction
14. Simulect induction is safer and more effective than OKT3 in kidney recipients older than 60 years
15. Comparison of basiliximab to rabbit anti-thymocyte globulin induction in kidney transplant recipients
16. A multicenter, randomized trial of Simulectâ versus Thymoglobulineâ in renal transplantation
17. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients
18. Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function
19. A calcimeurin-free strategy for induction immunosuppression for delayed graft function in cadaveric kidney transplantation
20. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus
21. A multicenter trial of Simulectâ in combination with Neoralâ, Cellceptâ and steroids for the prevention of acute rejection in kidney-pancreas transplantation: A low rate of rejection without recurrent diabetes mellitus
22. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival
23. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation
24. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
25. Reduction of acute renal allograft rejection by daclizumab
26. Can antibody prophylaxis allow sparing of other immunosuppressives
27. Zenapax versus OKT3 prophylaxis in immunologically high-risk kidney transplant recipients
28. Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation
29. One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function
30. Daclizumab decreases acute rejection in african american and hispanic renal transplant recipients
31. Daclizumab permits delayed introduction of calcineurin inhibitors in renal transplant recipients at risk for delayed graft funtion